Monte Rosa Therapeutics (GLUE) director awarded 25,800 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Monte Rosa Therapeutics director Kimberly Blackwell received a grant of stock options on Common Stock. The award covers 25,800 options, each with an exercise price of $17.10 per share, giving her the right to buy an equal number of shares in the future.

These options vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, as long as she continues serving until that time. After this grant, she holds 25,800 derivative securities from this award, which expire on June 11, 2036 if not exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Blackwell Kimberly

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,800	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 25,800 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 25,800 options Exercise price: $17.10 per share Underlying shares: 25,800 shares +2 more

5 metrics

Stock options granted 25,800 options Grant to director Kimberly Blackwell

Exercise price $17.10 per share Stock Option (Right to Buy) grant

Underlying shares 25,800 shares Common Stock underlying the options

Expiration date June 11, 2036 Option term end date

Shares after transaction 25,800 derivative securities Total options held from this award

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 17.1000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option shall vest and become exercisable in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/12/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blackwell Kimberly

(Last)

(First)

(Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON

MASSACHUSETTS

02118

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$17.1	06/11/2026		A		25,800		⁽¹⁾	06/11/2036	Common Stock	25,800	$0	25,800	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

	/s/ Markus Warmuth, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Monte Rosa Therapeutics (GLUE) report for Kimberly Blackwell?

Monte Rosa Therapeutics reported that director Kimberly Blackwell received a grant of 25,800 stock options. These options give her rights to buy common shares at a fixed $17.10 exercise price, functioning as equity-based compensation rather than an open‑market purchase.

How many Monte Rosa Therapeutics (GLUE) options were granted to Kimberly Blackwell?

Kimberly Blackwell was granted 25,800 stock options. Each option is linked to one share of Monte Rosa Therapeutics common stock, so the award covers rights over 25,800 underlying shares, subject to vesting conditions and future exercise decisions.

What is the exercise price of Kimberly Blackwell’s Monte Rosa (GLUE) stock options?

The exercise price of Kimberly Blackwell’s options is $17.10 per share. This means she can buy Monte Rosa Therapeutics common stock at $17.10 for each option once vested, regardless of the market price at the time of exercise.

When do Kimberly Blackwell’s Monte Rosa (GLUE) options vest and become exercisable?

The options vest in full on the earlier of June 11, 2027, or Monte Rosa Therapeutics’ next annual meeting of stockholders. Vesting is conditioned on her continued service with the company through that vesting date, according to the Form 4 footnote.

When do Kimberly Blackwell’s Monte Rosa Therapeutics (GLUE) options expire?

The stock options expire on June 11, 2036. If they are not exercised by that date, the rights to purchase the underlying Monte Rosa Therapeutics common shares at the $17.10 exercise price will lapse and become worthless.

Is Kimberly Blackwell’s Form 4 transaction a market purchase of Monte Rosa (GLUE) shares?

No, the Form 4 reflects a grant of stock options, not a market purchase. The transaction is coded as a grant or award, giving her the right to buy shares later, rather than indicating she bought or sold shares in the open market.